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S U MM A R Y  
Fighting metastasis is a major challenge in cancer therapy and novel therapeutic targets and drugs 
are highly appreciated. Resistance of invasive cells to anoikis, a particular type of apoptosis 
induced by loss of cell-extracellular matrix (ECM) contact, is a major prerequisite for their 
metastatic spread. Inducing anoikis in metastatic cancer cells is therefore a promising therapeutic 
approach. 
The vacuolar H+-ATPase (V-ATPase), a proton pump located at the membrane of acidic 
organelles, has recently come to focus as an anti-metastatic cancer target. As V-ATPase inhibitors 
have shown to prevent invasion of tumor cells and are able to induce apoptosis we proposed that 
V-ATPase inhibition induces anoikis related pathways in invasive cancer cells. 
In this study the V-ATPase inhibitor archazolid A was used to investigate the mechanism of 
anoikis induction in various metastatic cancer cells (T24, MDA-MB-231, 4T1, 5637). Therefore, 
cells were forced to stay in a detached status to mimic loss of cell-ECM engagement following 
treatment with archazolid.  
Indeed, anoikis induction by archazolid was characterized by decreased expression of the 
caspase-8 inhibitor c-FLIP and caspase-8 activation, thus triggering the extrinsic apoptotic 
pathway. Interestingly, active integrin β1, which is known to play a major role in anoikis 
induction and resistance, is reduced on the cell surface of archazolid treated cells. Furthermore, a 
diminished phosphorylation of the integrin downstream target focal adhesion kinase could be 
demonstrated. The intrinsic apoptotic pathway was initiated by the pro-apoptotic protein BIM, 
increasing early after treatment. BIM activates cytochrome C release from the mitochondria 
consequently leading to cell death and is described as one major inducer of anoikis in non-
malignant and anoikis sensitive cancer cells.  
Of note, we observed that archazolid also induces mechanisms opposing anoikis such as 
proteasomal degradation of BIM mediated by the pro-survival kinases ERK, c-Src and especially 
Akt at later time points. Moreover, induction of reactive oxygen species (ROS) influences BIM 
removal as well, as moderate levels of ROS have second messenger properties amplifying cell 
survival signals. Thus, to antagonize these anoikis escape strategies a combination of archazolid 
with proteasome or ROS inhibitors amplified cancer cell death synergistically. 
Most importantly, intravenous injection of archazolid treated 4T1-Luc2 mouse breast cancer cells 
in BALB/cByJRj mice resulted in reduced lung metastases in vivo. 
 
IV
To summarize this work we propose archazolid as a very potent drug in inducing anoikis 
pathways in metastatic cancer cells even though having learned that detachment together with 
treatment triggers multiple resistance mechanisms opposing cell death.  
Hence, V-ATPase inhibition is not only an interesting option to reduce cancer metastasis but also 
to better understand anoikis resistance and to find choices to fight against it. 
Figure 1: Anoikis, anoikis resistance and actions of archazolid 
A: Detachment induces cell death (anoikis) in non-malignant cells preventing a dysplastic growth of tissue 
cells in other locations, important for tissue homeostasis. Metastatic cancer cells develop anoikis 
resistance to survive in the circulation, which is a prerequisite for tumor metastasis. 
B: Archazolid induces anoikis in malignant cells, thus preventing metastasis.  
C: Archazolid treatment promotes anoikis by downregulation of active integrin on the cell surface, 
attenuating integrin signaling and inducing apoptosis. This is accompanied by mechanisms opposing 
anoikis induction like activation of certain survival signals and repression of apoptotic proteins. 
Nevertheless, anoikis signals outweigh anoikis repressing signals induced by archazolid treatment finally 
leading to cell death and reduced metastasis in vivo. 
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1 INTRODUCTION 
1.1 The V-ATPase as Cancer Target 
1.1.1 Physiological Function and Structure 
Vacuolar H+-ATPases (V-ATPases) are ATP-dependent proton pumps ubiquitously expressed, 
regulating the pH in endomembrane systems like endosomes, lysosomes, the Golgi apparatus and 
secretory vesicles thus affecting receptor-mediated endocytosis, protein degradation, membrane 
fusion and intracellular trafficking (1). Some specialized cell types even express the V-ATPase on 
their plasma membrane for acidification of the extracellular space needed e.g. for renal 
acidification or bone resorption (2,3).  
The V-ATPase is a large multisubunit complex (Figure 2) basically working by a rotary 
mechanism, organized in two major domains (V1 and V0). The V1 domain is located at the 
periphery of the cytoplasmic membrane side responsible for ATP hydrolysis providing energy for 
the rotary movement. It consists of eight different subunits (A-H). The central hexametric ring 
consists of three AB heterodimers building the catalytic site for ATP hydrolysis. Subunits C-H 
form peripheral and central stalks connecting V1 and V0. The central stalk functions as rotor 
transferring the energy of the hydrolysis in a rotation of a ring of proteolipid subunits in the V0 
domain.  
The V0 domain is embedded in the membrane conducting the proton translocation from the 
cytoplasm to the lumen. It consists of six different subunits (a, d, e, c, c´, c´´). The protons are 
translocated by two hemi-channels in the a-subunit and the rotation of the proteolipid ring of 
four c, c´and c´´ subunits. Each proteolipid contains a buried glutamate residue responsible for 
proton binding and transportation. Protons can enter the first hemi-channel in the a-subunit at 
the cytoplasmic side of the membrane and subsequently bind the glutamate residue of one c-
subunit. The proteolipid ring rotates, driven by ATP hydrolysis in the V1 domain thereby 
transporting the H+ to the second hemi-channel releasing the proton to the lumen (2). Although 
the V-ATPase is structurally and mechanically related to the F1F0 ATPase (F-ATPase) of 
mitochondria the V-ATPase cannot synthesize ATP from ADP and phosphate (4,5).  
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1.1.2 Role and Relevance in Cancer Cells 
It has been reported that cancer cells express V-ATPase on their plasma membrane to acidify the 
extracellular space, as low pH is important for invasion and proliferation (6–8).  Expression of V-
ATPase on the plasma membrane of breast cancer cells differs between highly metastatic and 
lowly metastatic cell lines. Cells with a more invasive phenotype had an increased V-ATPase 
expression and proton flux then non-invasive cell lines giving evidence that there is a correlation 
to the metastatic potential (8). It is known that cancer cells secret a variety of enzymes 
responsible for extracellular matrix degradation important for invasion and metastasis. These 
enzymes are most active at lower pH. Therefore, an acidification of the extracellular space is 
favorable for cancer cells (9). On the other hand plasma membrane V-ATPases may play an 
additional role in tumor cell growth and survival. Tumor cells are known to produce more H+ due 
Figure 2: Structure of the vacuolar H+-ATPase 
The V-ATPase is a proton pump responsible for the acidification of intracellular compartments. It is a 
multisubunit complex organized in two major domains (V1 and V0). The V1 domain is responsible for 
ATP hydrolysis to drive the rotary mechanism that translocates the protons in the V0 domain from the 
cytoplasm to the lumen. Protons can enter a hemi-channel in the a-subunit in the V0 domain and bind a 
glutamate residue in one of the c-subunits. By the rotation of the c-subunit ring, driven by ATP 
hydrolysis in the V1 domain, the proton is translocated to the second hemi-channel in the a-subunit 
releasing H+ to the lumen. Illustrated according to the model of Forgac, 2007.   
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to higher glycolytic activity (10). To circumvent cytosolic acidification the pH has to be tightly 
regulated. It has been shown that lactic acid accumulation due to enhanced glycolytic activity 
provokes the upregulation of several transporters including the V-ATPase resulting in a 
dysregulation of the solid tumor milieu favoring progression, invasion and metastasis (11). 
1.1.3 V-ATPase Inhibitors 
V-ATPases were shown to be overexpressed in highly metastatic cancer cells (8,12,13). There is 
also evidence that cancer cell treatment can enhance V-ATPase expression (14), on that account 
V-ATPase inhibitors might serve as potent anti-cancer drugs or sensitizer.  
1.1.3.1 Bafilomycins and Concanamycins 
Bafilomycins and concananmycins belong to the class of plecomacrolides first isolated from 
Streptomyces species already identified in the early 1980s (15–19). Bafilomycin was described as the 
first specific and highly potent V-ATPase inhibitor (18) but later concanamycin proved to have 
even higher specificity and inhibitory effects compared to bafilomycin (19,20).  
For both inhibitors it has been shown that they bind to the c-subunit in the V0 domain (21–24), 
suggesting a rotation block of the proteolipid c-subunit ring relative to the a-subunit or 
additionally preventing conformational changes in c-subunit and thereby inhibiting V-ATPase 
activity (23,25).  
1.1.3.2 Benzolactone Enamides 
A variety of cytotoxic compounds sharing a benzolactone enamide core structure showed V-
ATPase inhibitory potential comparable to plecomacrolides (26). All of them were first isolated 
from a variety of microorganisms such as marine sponges (salicylhalamides), tunicates 
(lobatamides), bacteria (oximidines) or myxobacteria (apicularen, cruentaren) (27).  
Recently, the binding site for apicularen was investigated showing that apicularen binds the c-
subunit in the V0 complex near the binding sites of plecomacrolides suggesting a similar mode of 
inhibition (28). 
1.1.3.3 Indolyls 
These are simplified synthetic structures based on bafilomycin with still active V-ATPase 
inhibitory function, developed after characterization of the key structural elements responsible 
for the biological activity of bafilomycin (29,30). They are widely used for V-ATPase research as 
they can be modified for different biophysical technics and approaches (31–33). 
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1.1.3.4 Archazolid a Macrolactone 
Archazolid is a myxobacterial secondary metabolite, first isolated from Archangium gephyra and 
Cystobacter violaceus (34,35) binding c-subunit in the V0 domain of the V-ATPase and thereby 
inhibiting its activity (36). Archazolid was tested to be a highly specific V-ATPase inhibitor with 
no effect on F-ATPases or Na+/K+-ATPases and an IC50 in the nanomolar range (36). 
Archazolid binds in the equatorial region of the c-subunit rotor in the V0 domain within helix 
four of the c-subunit and not like bafilomycin at the interface between two adjacent c-subunits. 
Still the mode of action is assumed to be the same as for bafilomycin by blocking the rotation of 
the c-ring relative to the a-subunit or shielding the glutamate residue essential for proton binding 
to the c-subunit (37).  
For archazolid A and B a total synthesis was achieved published 2007 and 2009 (38,39) 
Archazolids are composed of a macrocyclic lactone ring with a thiazole side chain (Figure 3)(27).  
In the last few years our group showed that archazolid is affecting motility of invasive cancer cells 
as well as induction of apoptotic cell death (40–42). We therefore hypothesized that archazolid 
might also affect the initial steps of metastatic dissemination which is characterized by the ability 
of invasive tumor cells to survive in a state of detachment from the extracellular matrix (ECM) 
(43).  
 
 
Figure 3: Structure of archazolid 
R= CH3: archazolid A 
R= H: archazolid B 
Structure adapted from Huss et al., 2009 (27) 
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1.2 Anoikis 
Anoikis is a term first introduced by Frisch et al., 1994 describing the phenomenon that cells 
deprived of extracellular-matrix-attachment underwent classical apoptosis. They defined the 
expression anoikis for this occurrence, meaning “the state of being without a home, or homeless; 
Greek” (44). The significant findings of this paper were firstly, that attachment signals are 
mandatory to prevent activation of programmed cell death and that integrins play a crucial role in 
this event. Secondly, that detachment-induced-apoptosis requires the mitochondrial 
permeabilisation as known for the intrinsic apoptotic pathway and thirdly, that sensitivity towards 
anoikis differs significantly between cell types (45).  
Anoikis is a specific type of apoptosis initiated by detachment of cells from their respective ECM. 
This is an important physiological process to maintain tissue homeostasis (46).  
Anoikis is comprised of elements of the intrinsic and extrinsic apoptotic pathway together with 
the loss of survival signals. Vachon (2011) proposed a “four-punch” hypothesis for cell death 
induction by detachment. The first “punch” is the deactivation of integrin downstream signals 
like the focal adhesion kinase (FAK) and/or c-Src kinase and thereby inhibition of the PI3K/Akt 
and Ras/Raf/MEK/ERK survival pathway. As second “punch” he determined the simultaneous 
disassembly of anchoring focal adhesions largely by loss of integrin-mediated adhesion and 
destabilization of the cytoskeleton. The third “punch” is described as the activation of pro-
apoptotic proteins triggering intrinsic apoptosis. The fourth “punch” finally is the induction of 
the extrinsic apoptotic pathway by caspase-8 activation (47).  
1.2.1 Loss of Adhesion-Signaling 
Anoikis is initiated by the disruption of integrin ligation to the ECM. Integrin binding activates 
distinct cell survival signaling cascades comprising downstream players such as FAK, c-Src 
kinase, PI3K/Akt and the extracellular signal-regulated kinase (ERK). Detachment of cells, 
meaning, loss of integrin signaling not only inhibits survival signals but also activates specific 
apoptotic processes (45,47,48). 
The survival cascades activated via integrin ligation inhibit pro-apaptotic players like the Bcl-2 
protein-family members BIM, Bad, Bax as well as several caspases and activate, transcriptionally 
or by direct interactions, anti-apoptotic players like the FLICE-like inhibitory protein (c-FLIP) 
(45,47,49). It has also been demonstrated that production of moderate levels of reactive oxygen 
species (ROS) upon integrin engagement can transduce pro-survival signals protecting from 
anoikis by activating kinases (Figure 4) (50).  
INTRODUCTION 7 
Consequently, disruption of the integrin signaling inactivates kinase phosphorylation and pro-
survival signal transduction and additionally triggers changes in the cytoskeleton releasing and 
activating pro-apoptotic proteins (47). Also ROS levels drop dramatically when cells are in 
suspension depriving them of the beneficial kinase activating function (50,51).  
 
 
1.2.2 Induction of the Intrinsic and Extrinsic Apoptotic Pathway 
Anoikis, in line with classical apoptosis can follow the extrinsic pathway, triggered by cell surface 
death receptors or the intrinsic pathway driven by activation of pro-apoptotic proteins leading to 
permeabilization of mitochondria (46,52). Activation of caspase-8 is considered as a major player 
of the extrinsic pathway and the activation of pro-apoptotic members of the Bcl-2 family, in 
particular the protein BIM and mitochondrial cytochrome C release are features of the intrinsic 
pathway of anoikis. However, a crosstalk between intrinsic and extrinsic pathways frequently 
occurs (Figure 5) (53–55). 
Figure 4: Integrin signaling upon ECM attachment 
Integrin-ECM interaction recruits and activates several kinases like the focal adhesion kinase (FAK), 
PI3K and c-Src activating downstream Akt, ERK and c-FLIP, leading to the inhibition of pro-apoptotic 
proteins. On the other hand activated Akt and ERK initiate pro-survival and proliferative signaling 
cascades leading to cell growth. 
Figure adapted from Charugi et al., 2008 and Vachon, 2011 
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1.2.3 The Role of BIM in Anoikis Induction 
BIM is thought to be a major inducer of the intrinsic anoikis pathway as it has been reported that 
BIM increases rapidly after detachment of anoikis sensitive cells. Additionally, downregulation of 
BIM by RNA interference (RNAi) inhibited anoikis in these cells. Detachment-induced 
expression of BIM requires integrin β1 detachment, downregulation of EGF receptor and 
inhibition of ERK signaling (48,54). BIM expression and release is tightly regulated. On the one 
hand BIM can be sequestered by the myosin motor complex when cells are ECM-attached (56). 
On the other hand the Akt pathway inhibits BIM gene-transcription and active Akt as well as 
active ERK phosphorylate BIM to be degraded by the proteasome or otherwise removed from 
the cytosol (57,58). 
If BIM is released upon detachment it translocates to the mitochondria leading to cytochrome C 
release by activation of Bax and Bak oligomerization triggering classical apoptotic pathways like 
the apoptosome formation, caspase activation and DNA fragmentation (59,60). 
Figure 5: Detachment induced cell death – anoikis 
Detachment induced cell death is initiated by the loss of integrin-ECM engagement leading to the loss of 
survival signals mediated by FAK, c-Src and the PI3K pathway. Disruption of focal adhesions also leads 
to cytoskeletal instability by loosing the direct ECM-cytoskeletal link. Next, pro-apoptotic proteins like 
BIM are activated, followed by cytochrome C release from the mitochondria. Together with active 
caspase-8 triggered by death receptors or unligated integrins effector caspases are cleaved conducting 
programmed cell death.  
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Detachment triggers BIM release and increase in three ways. Firstly, it is set free from the myosin 
motor complex and accumulates in the cytosol, secondly Akt no longer inhibits BIM expression 
and thirdly attenuated Akt and ERK signaling inhibit proteasomal degradation and sequestration 
of the released BIM, which all together leads to increased BIM occurrence in the cytosol.  
1.2.4 Caspase-8 Induction by Detachment 
Caspase-8 activation as key feature of the extrinsic apoptosis-induction is reported to be involved 
in anoikis. Caspase-8 can induce apoptosis in two ways: High caspase-8 activation is sufficient to 
activate effector caspases leading directly to cell death, as low caspase-8 activation triggers the 
mitochondrial pathway via Bid cleavage. Cleaved Bid indirectly activates effector caspases via 
cytochrome C release. The mode of action of how caspase-8 induces cell death is also cell type 
specific (45,47,55). Caspase-8 is predominantly activated by death receptors binding death ligands 
(tumor necrosis factor-α, FasL, TRAIL) recruiting the Fas-associated death domain protein 
(FADD). FADD together with procaspase-8 form the death inducting signaling complex (DISC) 
resulting in cleavage and thereby activation of caspase-8 (47). Detachment induced apoptosis is 
clearly supported by the induction of caspase-8. There is evidence that caspase-8 can be recruited 
and activated by unligated integrins (61). Additionally, ligand bound integrin can indirectly inhibit 
procaspase-8 cleavage: FAK, c-Src and the MAP-kinase pathway hamper procaspase-8 from 
being activated, either by inhibiting the autoproteolytic activation of procaspase-8 or preventing 
FADD recruitment to form the DISC complex. This is implemented by phosphorylation of 
either the FADD or procaspase-8 or by activation of c-FLIP a known caspase-8 suppressor 
(46,47,62,63).   
1.3 Anoikis Resistance and Metastasis 
Whereas non-tumoral cells respond to loss of cell-matrix contact by induction of anoikis (44,64), 
metastatic cancer cells are resistant. This allows their survival after detachment from the primary 
tumor and their travel through the bloodstream to distant organs (44,64). In other words, anoikis 
resistance is a prerequisite and a hallmark for the metastatic spread of tumor cells (52). Integrin 
signaling has also been connected with chemoresistance as it can reduce drug- and even 
radiation-induced apoptosis (63). 
Inducing anoikis by drugs is a promising option for the treatment of metastatic cancer but calls 
for a profound understanding of the mechanisms underlying anoikis resistance in invasive cancer. 
INTRODUCTION 10 
Therefore, anoikis resistance mechanisms will be more deeply elucidated in the upcoming 
sections and are summarized in Figure 6. 
1.3.1 Integrin Alterations 
A strategy to evade anoikis is a switch in the integrin repertoire either by modifying integrin 
expression or changing the existing repertoire (56). As integrins are composed of two subunits (α 
and β) and each αβ combination has special binding and signaling properties (65) a switch from 
anoikis-sensitizing integrins to anoikis-suppressing ones is desired. This was described e.g. for 
squamous cell carcinoma as unligated αvβ5 triggered apoptosis whereas αvβ6 activated the 
PI3K/Akt pathway (66). Another example is unligated integrin β3, which can recruit and activate 
c-Src causing tumor cell survival. Therefore targeting cancer with specific integrin antagonists is a 
promising approach in tumor treatment and already tested in Phase II clinical trials (67). Integrins 
are also known to collaborate with growth factor receptors. Integrins can activate growth factor 
receptors in a ligand-independent manner by organizing signaling platforms (63). These signaling 
platforms are cholesterol-enriched membrane microdomains (CEMMs) regulating the localization 
and coupling of effector molecules and are normally internalized following detachment. This is 
mediated by caveolin-1 (Cav1) as Cav1 absence impairs CEMM internalization leading to 
increased signaling through e.g. Ras/Raf/MEK/ERK and PI3K/Akt (68).   
1.3.2 Activation of Pro-Survival Signaling 
To bypass signaling that would lead to anoikis, tumor cells can constitutively activate downstream 
pro-survival pathways (e.g. PI3K/Akt, ERK) by autocrine secretion of growth factors or over-
expression of different receptor tyrosin kinases transducing survival signals (56).  
To circumvent activation of the extrinsic apoptotic pathway malignant cells overexpress c-FLIP, 
an endogenous antagonist of caspase-8 with higher affinity for the DISC (52,55).  
1.3.3 Targeting BIM Induction 
By detachment BIM accumulates in the cytoplasm and translocates to the mitochondria 
triggering cytochrome C release leading to caspase-9 and caspase-3 activation inducing cell death. 
BIM is a key player in anoikis induction in various cancer cells. Therefore, metastasis requires 
attenuation of BIM. This can be achieved again by constitutive activation of Akt and ERK 
responsible for BIM degradation and transcription (69,70). 
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1.3.4 Reactive Oxygen Species 
As mentioned, moderate levels of ROS induced by integrin engagement can activate c-Src kinases 
enhancing survival (50). Elevated ROS levels are often reported in solid tumors and cancer cell 
lines changing the tumor micro-enviroment (52). Oxidative stress in tumor cells is controversially 
discussed: On the one hand elevated ROS levels contribute to anoikis induction as the level of 
ROS was shown to correlate with the extend of cell death (71). On the other hand, elevated ROS 
levels are detected during metastasis with a protective effect as treatment with ROS scavenger 
increased apoptosis (50). If ROS production is beneficial for tumor cells it is probably context 
and level dependent. 
1.3.5 Other Mechanisms  
Anoikis resistance can be achieved through many different actions. One additional survival 
strategy is the induction of autophagy by detachment, a survival mechanism preventing anoikis. It 
has been shown that inhibition of autophagy increased caspase-3 activity in detached cells 
enhancing apoptosis (72). BIM was also suggested to play a role in autophagy by interacting with 
beclin-1 and inhibiting autophagosome formation (73). Autophagy can be used to survive 
unfavorable conditions like hypoxia or nutrition shortage by driving cells in a dormant state, with 
reactivation of metabolism and cell cycle when conditions improve, important for cancer cell 
metastasis. In anoikis resistance the reduced integrin signaling induces autophagy delaying the 
onset of apoptosis by sustaining ATP levels (56,74,75). It has been shown that specific blockage 
of β1 integrins is sufficient to induce autophagy. There are several ways described how ECM 
signaling can influence the autophagy machinery. One proposed mechanism is, that FAK, the 
downstream target of integrin, can indirectly inhibit mTOR. As mTOR is a classical autophagy 
inhibitor, loss of FAK leads to mTOR inhibition activating autophagy (74). 
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Figure 6: Anoikis resistance mechanisms 
Anoikis resistance can be achieved by multiple actions. Cells can change or overexpress their integrin 
repertoire or activate survival kinases ligation independent. Inducing the proteasomal degradation of BIM 
or inhibiting BIM expression is another strategy to avoid cell death. By overexpression of c-FLIP, 
caspase-8 activation is repressed. Additionally, induction of ROS can activate survival kinases.   
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1.4 Aim of the Study 
The cause of death by cancer is mainly not the primary tumor but the development of metastases 
in distinct organs (76). Metastasis is a highly complex process following sequential steps that 
comprise dissociation of cancer cells from the site of origin, their survival and travel in the 
circulation as well as migration and proliferation in distinct target organs (55,75,77). Due to the 
clinical importance there is still the need to better understand the major determinants of 
metastasis and to identify therapeutical targets and pathways suitable for fighting the metastatic 
process.  
Our Group recently introduced the V-ATPase as a promising new anti-metastatic target showing 
that the V-ATPase inhibitor archazolid inhibits cancer cell migration (Figure 7) (40).  
 
 
One prerequisite for cancer cell metastasis is the ability of cancer cells to detach from the solid 
tumor and survive and travel in the bloodstream to form metastasis. Normal tissue cells are 
prevented to detach and colonize elsewhere by a process called anoikis. This is a type of 
apoptotic cell death induced by the loss of cell-to-extracellular matrix connection.  
  
The aim of this study was to investigate the effects of archazolid A on anoikis resistant tumor 
cells and to reveal if anoikis specific pathways are activated due to archazolid treatment.  
 
Cancer Cell Anoikis Resistance Metastasis
Archazolid A
?
Figure 7: V-ATPase inhibition blocks metastasis 
It was shown that V-ATPase inhibition by archazolid diminishes cancer cell migration and metastasis. 
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2 MATERIALS & METHODS 
2.1 Materials 
2.1.1 Compounds 
Archazolid A was purified and isolated as described previously provided by the group of Rolf 
Müller (35). Concanamycin A was purchased from Enzo Life Science GmbH (Lörrach, 
Germany). Both compounds were solved in DMSO and stored at -20°C.  
2.1.2 Chemicals, Inhibitors, Dyes and Reagents 
Table 1: Inhibitors   
Inhibitor Distributor/Producer  
Bortezomib (proteasome-inhibitor)  
Complete® mini EDTA free 
LY 294002 (Akt-inhibitor) 
MG-132 (proteasome-inhibitor) 
Na3VO4 
NaF 
PD 98059 (ERK-inhibitor) 
Phenylmethylsulfonyl fluoride (PMSF) 
Saracatinib (Src-inhibitor) 
Selleck Chemicals, Munich, Germany 
Roche diagnostics, Penzberg, Germany 
Selleck Chemicals, Munich, Germany 
Selleck Chemicals, Munich, Germany 
ICN Biomedicals, Aurora, OH, USA 
Merck, Darmstadt, Germany 
Selleck Chemicals, Munich, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
Selleck Chemicals, Munich, Germany 
Table 2: Dyes, reagents and chemicals 
Reagent Distributor/Producer  
Accustain® paraformaldehyde (PFA) 
Ac-LETD-AFC (caspase-8) 
Agarose SeaPlaque® (low melting temp.) 
Bovine serum albumin (BSA) 
BCA Protein Assay Reagent (Kit) 
DCFDA (2’,7’-dichlorofluorescin diacetate) 
DMEM (high glucose) 
Dimethylsulfoxid (DMSO) 
EDTA 
EGTA  
Fetal calf serum gold (FCS gold) 
Fibronectin 
FluorSaveTM Reagent mounting medium 
Sigma-Aldrich, Taufkirchen, Germany 
Bachem, Bubendorf, Germany 
Lonza Rockland, ME, USA 
Sigma-Aldrich, Taufkirchen, Germany 
Thermo Fisher Scientific, Schwerte, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
PAA Laboratories, Pasching, Austria 
AppliChem, Darmstadt, Germany 
Carl Roth, Karlsruhe, Germany 
AppliChem, Darmstadt, Germany 
PAA Laboratories, Pasching, Austria 
BD Bioscience, Heidelberg, Germany 
Merck, Darmstadt, Germany 
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Glutamine 
Glycine 
Hoechst (bisBenzimide H33342) 
LysoTracker® dye  
McCoy´s Medium 
Methylcellulose  
MTT (Thiazolyl Blue Tetrazolium Bromide) 
N-Acetyl-L-Cystein (NAC) 
Na-luciferin 
Non-fat dry milk poweder (Blotto)  
Page RulerTM Prestained Protein Ladder 
Penicillin/Streptomycin 100x 
Polyacrylamid (Rotiphorese® Gel A 30%) 
Poly(2-hydroxyethyl methacrylate)  
(Poly-HEMA) 
Propidium Iodide  
Rhodamin-Phalloidin (R415) 
RPMI 1640 
Triton X-100 
Trypsin 
Tween®100 
Sigma-Aldrich, Taufkirchen, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
Moleculare Probes, Darmstadt, Germany 
PAA Laboratories, Pasching, Austria 
Sigma-Aldrich, Taufkirchen, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
Promega Cooperation, Madison, WI, USA 
Carl Roth, Karlsruhe, Germany 
Fermentas, St. Leon-Rot, Germany 
PAA Laboratories, Pasching, Austria 
Carl Roth, Karlsruhe, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
 
Sigma-Aldrich, Taufkirchen, Germany 
Invitrogen, Karlsruhe, Germany 
PAN Biotech, Aidenbach, Germany 
Merck, Darmstadt, Germany 
PAN Biotech, Aidenbach, Germany 
BDH/Prolabo®, Ismaning, Germany 
All other biochemicals, reagents and dyes not listed in Table 2 were purchased either from Sigma-
Aldrich, AppliChem, Carl Roth or Merck.  
2.1.3 Buffer and Media 
Table 3: Commonly used buffers 
Buffer Composition 
PBS (pH 7.4) NaCl (123.2mM), Na2HPO4 (10.4mM), KH2PO4 (3.2mM) in H2O 
PBS+ Ca2+/Mg2+  
(pH 7.4) 
NaCl (136.9mM), KCl (2.7mM), Na2HPO4 (8.1mM), KH2PO4 
(1.5mM), MgCl2 (0.5mM), CaCl2 (0.7mM) in H2O 
DMEM  DMEM high glucose (500ml), FCS gold (50ml), Penicillin (10,000U/ml)/Streptomycin (10mg/ml) (5ml) 
RPMI RPMI 1640 (500ml), FCS gold (50ml), Penicillin (10,000U/ml)/Streptomycin (10mg/ml) (5ml) 
McCoy´s McCoy´s (500ml), FAC gold (50ml), Glutamine (1.5mM, 5ml), Penicillin (10,000U/ml)/Streptomycin (10mg/ml) (5ml) 
Trypsin/EDTA Trypsin (0.05%), EDTA (0.02%) in PBS 
HFS-solution Sodium citrate (0.1%), Triton X-100 (0.1%) in PBS 
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Table 4: Buffers for protein lysis and Western blot analysis 
Buffer Composition 
Phospho-lysis buffer 
(pH 7.5) 
EDTAx2H2O (2mM), NaCl (137mM), Glycerol (10%), 
Na4P2O7x10H2O (2mM), Tris-Base (20mM), Triton X-100 (1%), 
C3H7Na2O6Px5H2O (20mM), NaF (10mM), Na3VO4 (2mM)*, 
PMSF (1mM)*, Complete® mini EDTA free (4mM)*in H2O 
Digitonin lysis buffer** 
(pH 7.2) 
(mito-fractionation) 
Mannitol (210mM), Sucrose (200mM), Hepes (pH 7.2, 10mM), 
Na2EGTA (0.2mM), Succinate (5mM), BSA (0.15%), Digitonin 
(80µg/ml) in H2O 
5X SDS sample buffer 
TrisHCl (pH 6.8) (3.125mM), Glycerol (10ml), SDS (5%), 
DTT (2%), PyroninY (0.025%), in H2O 
Stacking gel 
Polyacrylamid solution (40%), Tris HCl pH 6.8 (125mM), SDS 
(0.1%), TEMED (0.2%), APS (0.1%) in H2O 
Separation gel 12% Polyacrylamid solution (40%), Tris HCl pH 8.8 (375mM), SDS (0.1%), TEMED (0.1%), APS (0.05%) in H2O 
Elektrophoresis buffer Tris-Base (4.9mM), Glycine (38mM), SDS (0.1%) in H2O 
Tank buffer 5X Tris-Base (240mM), Glycine (195mM), in H2O 
Tank buffer 1X Tank buffer 5X (20%), Methanol (20%) in H2O 
TBS-T (pH 8.0) Tris-Base (24,76mM), NaCl (189.9mM), Tween 20 (0.1%) in H2O 
* added immediately before usage 
** prepared ≤ 30min before usage 
Table 5: Buffers for caspase activity measurement 
Buffer Composition 
Lysis buffer  MgCl2 (5mM), EGTA (1mM), Triton X-100 (0.1%), HEPES (25mM) in H2O 
Buffer B (pH 7.5) HEPES (50mM), Sucrose (1%), CHAPS (0.1%) in H2O 
Substrate solution Ac-LETD-AFC (56.25µM), DTT (0.2%) in Buffer B 
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2.1.4 Antibodies Used for Confocal Microscopy, Western Blot and FACS 
Analysis 
Table 6: Primary antibodies used for immunoblotting 
Antigen Source Dilution In Distributor/Producer 
Actin 
Akt 
Akt pSer473 
BIM 
COX IV 
Cytochrome C 
ERK 
ERK pThr202/Tyr204 
FAK 
FAK pTyr397 
c-FLIP 
Src 
Src pTyr416 
Tubulin beta 
VDAC 
mouse 
rabbit 
mouse 
rabbit 
rabbit 
rabbit 
rabbit  
mouse 
mouse 
rabbit 
rabbit 
mouse 
rabbit 
rabbit 
rabbit 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
1:1,000 
BSA 1% 
BSA 5% 
Blotto 5% 
BSA 5% 
Blotto 5% 
Blotto 5% 
Blotto 5% 
Blotto 5% 
BSA5 % 
BSA 5% 
BSA 5% 
Blotto 5% 
BSA 5% 
BSA 5% 
BSA 5% 
Merck Millipore (MAB 1501) 
Cell Signaling (9272) 
Cell Signaling (4051) 
Cell Signaling (2819) 
Cell Signaling (4844) 
Cell Signaling (4272) 
Cell Signaling (9102) 
Cell Signaling (9106) 
Santa Cruz (1688) 
Santa Cruz (11765) 
Cell Signaling (8510) 
Cell Signaling (2110) 
Cell Signaling (6943) 
Cell Signaling (2146) 
Cell Signaling (4866) 
Table 7: Secondary antibodies used for immunoblotting  
Antibody Dilution In Distributor/Producer 
Goat-anti-mouse IgG1 HRP  
Goat-anti-mouse IgG HRP 
Goat-anti-rabbit IgG HRP 
Goat-anti-mouse IRDye® 800cw 
Goat-anti-rabbit AlexaFluor® 680 
1:10,000 
1:10,000 
1:10,000 
1:20,000 
1:20,000 
Blotto 1% 
BSA 1% 
Blotto 1% 
Blotto 1% 
Blotto 1% 
Biozol 
Santa Cruz (2005) 
Bio-Rad 
 Li-COR GmbH 
Molecular Probes 
Table 8: Primary and secondary antibodies used for confocal microscopy or FACS analysis 
Antigen/Antibody Dilution Distributor/Producer 
Integrin β1 
Integrin β1 active form (12G10) 
Vinculin 
Goat-anti-mouse AlexaFluor® 488 
Goat-anti-rabbit AlexaFluor® 488 
1:400 
1:400 
1:100 
1:400 
1:400 
Cell Signaling (4706) 
Abcam (30394) 
Santa Cruz (25336) 
Molecular Probes 
Molecular Probes 
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2.2 Methods 
2.2.1 Cell Culture 
The human urinary carcinoma cell line T24 was provided by Dr. B. Mayer (Surgical Clinic, LMU, 
Munich) in 2009 and authenticated in April 2013 by the DSMZ (Braunschweig, Germany) by 
DNA profiling of eight highly polymorph short tandem repeat (STRs) regions. Cells were 
cultured in McCoy´s medium supplemented as described in Table 3 at 37°C and 5% CO2 
(Heraeus, Hanau, Germany). MDA-MB-231 and 5637 cells were purchased from CLS cell lines 
service GmbH (Eppelheim, Germany) in May 2011 and April 2013. CLS authenticates all cell 
lines by DNA profiling via STR-analysis. The mouse breast cancer cell line 4T1-Luc2 was 
purchased from Caliper Life Science (USA) in January 2012. Caliper analyzed the cells by 
IMPACT 1 PCR profiling. 4T1-Luc2 and 5637 cells were maintained in RPMI-1640 medium and 
MDA-MB-231 cells in DMEM (High Glucose) (medium supplements see Table 3).   
2.2.1.1 Passaging and Seeding 
For passaging (1:10, every 3-4 days), growth medium was removed and cells were washed once 
with warm PBS. Cells were detached by incubation with 2ml Trypsin/EDTA for 5min at 37°C 
(75cm2 flask). 7ml stopping-medium containing FCS was added to saturate the Trypsin. Cells 
were centrifuged (1,000rpm, 5min, RT), the pellet resuspended in medium and seeded in a new 
culture flask or well plate. To measure cell concentration and viability the VICELLTM cell viability 
analyzer (Beckman Coulter, Krefeld, Germany) was used.  
2.2.1.2 Freezing and Thawing 
For freezing, cells were harvested and counted as described in the previous section. Per cryovial 
2x106 cells were pipetted, centrifuged (1,000rpm, 5min, RT), resuspended in 900µl freezing-
medium containing 20% FCS and aliquoted in cryovials (900µl per vial). Now 100µl DMSO were 
added to each vial and stored at -20°C for 24h. Afterwards aliquots were moved to -80°C and 
finally stored in liquid nitrogen.  
For thawing, the cryovial was warmed in a water bath to 37°C and the content was immediately 
dissolved in 10ml pre-warmed medium. To remove the remaining DMSO cells were centrifuged 
(1,000rpm, 5min, RT), resuspended in growth medium and transferred in a 25cm2 cell culture 
flask. 
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2.2.2 LysoTracker Staining for Confocal Microscopy 
To stain cells for confocal microscopy 70,000 cells/well were seeded on IBIDI slides (IBIDI, 
Martinsried, Germany) one day before treatment. After the indicated treatment time cells were 
stained with 250µl/well LysoTracker® dye (100nM) and Hoechst (0.05µg/ml, nuclei staining) in 
PBS+ for 30min, 37°C. Subsequently, cells were imaged by confocal microscopy (LSM 510 Meta, 
Zeiss, Oberkochen, Germany) without fixation.  
2.2.3 Cell Adhesion by Impedance Measurements 
The XCELLigenceTM Real-Time Cell Analyzer (RTCA) system (Roche Diagnostics, Mannheim, 
Germany) was used to analyze adherence time of pretreated T24 cells. Therefore 5x103 cells/well 
were seeded in the respective electrode plate (E-Plate 16) after 24h prestimulation. Cell 
impedance was measured and adhesion time analyzed using the manufacturer's software 
(Software RTCA 1.2.1). There, the impedance is expressed as Cell Index (CI) a dimensionless 
parameter based on relative impedance changes. The CI baseline is defined by the electric 
conductance of the medium and increases upon cell-electrode contact while cells adhere to the 
surface. The slopes over the first 4h were analyzed and compared.  
2.2.4 Focal Adhesion Staining for Confocal Microscopy  
T24 cells were seeded in 12-well plates (100,000 cells/well) and treated with archazolid (10nM, 
24h) the day after. To stimulate focal adhesion formation, IBIDI slides (IBIDI, Martinsried, 
Germany) were coated with fibronectin (25µg/ml, 2h, 37°C then 2% BSA in PBS+, 1h, 37°C) 
before adding the cells (40,000 cells/well in 250µl growth medium). After 30min at 37°C 
incubation time cells were washed once with PBS+, fixed with 4% PFA (15min, RT) washed 
again and permeabilized with 0.1% Triton X-100 in PBS (2min, RT). Washed cells were blocked 
for 15min with 2%BSA/PBS+ to block unspecific binding. Thereafter, cells were incubated for 
1h at 4°C with vinculin antibody diluted in 2%BSA/PBS. After three washing steps the 
secondary AlexaFluor® 488 antibody was applied together with rhodamine-phalloidine for F-
actin staining  (1h, dark, RT in 2%BSA/PBS). Again, cells were washed three times with PBS+ 
and embedded in FluorSaveTM Reagent mounting medium and covered with a glass coverslip. 
Images were taken by confocal microscopy (LSM 510 Meta, Zeiss, Oberkochen, Germany).  
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2.2.5 In Vivo Experiments 
Twenty, 4-6 weeks old female BALB/cByJRj mice (Janvier) were housed in individually 
ventilated cages with a 12h day/night cycle and food and water ad libitum. Mice were injected with 
archazolid pretreated (10nM, 24h) or untreated 4T1-Luc2 cells (1x105) via the tail vein. 
Bioluminescence of metastasized cells was monitored at day 8 after cell injection under anesthesia 
(2% isoflurane in oxygen) using the IVIS Lumina system with Living Image software 3.2 (Caliper 
Life Sciences) 15 minutes after intraperitoneal injection of 6mg Na-luciferin (Promega). 
Thereafter mice were sacrificed by cervical dislocation, their lungs harvested, imaged and 
weighted. The total flux/area of the defined region of interest was calculated as 
photon/second/cm2. All in vivo experiments were performed according to the guidelines of the 
German law for protection of animal life and approved by the local ethics committee.  
In vivo experiments were performed by Laura Schreiner and Rebekka Kubisch. 
2.2.6 Colony Formation Assay 
Archazolid treated T24 cells (5x103, 24h) were suspended in a 0.4% agarose-medium mix 
(50%/50%), (low melting temperature agarose, LONZA) and seeded on 6-well-plates precoated 
with 1% agarose. Cells were incubated for 9 days at 37°C to proliferate and form viable 3D 
colonies. Evolved colonies were stained with MTT dye, photographed and analyzed by ImageJ 
1.46r software. On that account an ImageJ-macro was developed to automatize colony-counting 
and -size analysis.  
2.2.6.1 ImageJ Macro 
First, a circle with constant properties (h=966px, w=956px) was cut out of each photographed 
well, only containing stained colonies and no plastic surrounding and pasted in a new file. 
Pictures have to be in grayscale to be processed by this macro, otherwise they should be 
converted first. 
Then the following macro was used on the file converting the photograph in a black and white 
picture were only stained colonies of a size between 2-20px appear black. The “Watershed” 
command was used to split overlaid colonies. At the end the macro releases a table with the 
number and size of all counted colonies. 
 To first adjust and then verify the accuracy of the macro three wells were counted by hand and 
compared to the results of the macro.   
 
 
MATERIALS & METHODS  22 
 
Table 9: ImageJ macro counting stained colonies from the colony formation assay 
Macro commands (in sequence) Meaning 
run("Subtract Background...", "rolling=50 light"); 
Removes smooth, continuous, bright 
backgrounds behind dark objects based 
on the “rolling ball” algorithm  
run("Sharpen"); Sharpens all objects in the image 
setAutoThreshold("Default"); 
//run("Threshold..."); 
setThreshold(0, 197); 
run("Convert to Mask"); 
All colonies with an intensity over 197 
are selected and converted to a binary 
black and white image, where selected 
colonies appear black 
run("Watershed"); 
If some colonies are merged together 
they can be separated by this command 
run("Analyze Particles...", "size=2-20 
circularity=0.00-1.00 show=Masks display clear 
summarize record"); 
Now the size and number of the particles 
are analyzed and recorded in a table 
2.2.7 Detachment-Induced Anoikis Assay 
T24, MDA-MB-231, 4T1 or 5637 cells (7x104/well) were kept in suspension by using poly-
HEMA (poly(2-hydroxyethyl methacrylate)) coated 24-well plates to prevent adhesion (78,79). 
Poly-HEMA was dissolved as a stock solution in 99% EtOH (120mg/ml). To coat culture dishes 
with poly-HEMA the stock solution was diluted right before use 1:10 with 99% EtOH and 
warmed in a water bath to prevent precipitation. All wells were filled with the solution until the 
bottom was completely covered and dried open under the flow for at least 3h until all EtOH 
evaporated. The growth medium was supplemented with 1% methylcellulose to increase viscosity 
to prevent cell clumping of the floating cells. Here, cells were treated with archazolid right after 
seeding them in poly-HEMA coated wells. Apoptotic death was analyzed as described by 
Nicoletti et al. (80). After the indicated treatment time, cells were harvested, transferred to FACS 
tubes, washed once with ice-cold PBS (600g, 5min, 4°C) and resuspended in HFS- or PBS-
solution containing propidiumiodide. Permeabilized cells stained with propidiumiodide (PI, 
50 µg/µl) were analyzed for their sub-diploid DNA content by flow cytometry (FACSCanto II, 
BD), as DNA fragmentation is characteristic for late apoptosis. Cell death was further analyzed 
by the PI exclusion assay counting PI positive (5µg/µl), non-permeabilized cells by flow 
cytometry. All experiments were analyzed by FlowJo 7.6 software.   
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2.2.8 Flow Cytometry Analysis of Cell Surface Integrin
Active integrin β1 on the cell surface was examined using a conformation specific integrin β1 
antibody as for total integrin β1 a not conformation specific one was used. Floating and adherent 
cells were treated with archazolid (10nM, 24h), harvested on ice (adherent cells were trypsinized 
with trypsin/EDTA first), transferred to FACS tubes, washed once with ice-cold PBS (600g, 
5min, 4°C) and incubated with the respective integrin β1 antibody (45min, 4°C in 0.01% 
BSA/PBS). After washing with PBS cells were incubated with a fluorescent secondary antibody 
(45min, 4°C in 0.01% BSA/PBS) and analyzed by flow cytometry. The experiments were 
analyzed by FlowJo 7.6 software. 
2.2.9 Caspase Activity 
After treating cells with archazolid (1nM, 10nM, 48h) the activity of caspase-8 was measured 
using a commercial caspase-8 activity assay (Calbiochem) based on the cleavage of a caspase-8 
specific AFC (7-amino-4-trifluoromethyl coumarin) labeled peptide sequence. Therefore, cells 
were harvested, washed once with ice-cold PBS and lysed by the caspase lysis buffer and stored 
over night at -80°C. The next day, the cell lysat was centrifuged (14,000rpm, 10min, 4°C) to 
sediment cell debris and the supernatant was transferred to a new vial. Protein concentration was 
determined by the BCA assay.  
For measurement 10µl of each sample was pipetted in a non-transparent 96-well plate in 
triplicates. Now, 90µl of the freshly made substrate solution containing the labeled peptide 
sequence was added to each well.  The fluorometric shift over 5h at 37°C was monitored by a 
fluorescent plate reader (SpectraFluorPlus, Tecan, Männedorf, Austria) calculating the relative 
enzyme activity displayed as the relative fluorescence signal (RFU).  
2.2.10 Intracellular ROS Level 
Reactive oxygen species (ROS) were measured by using the 2′, 7′-dichlorofluorescin diacetate dye 
(DCFDA, Sigma-Aldrich), which is a cell-permeable non-fluorescent probe, trapped intracellular 
by de-esterification and fluoresces upon oxidation. Cells were harvested after incubation with the 
indicated substances and stained with 20µM DCFDA for 30min at 37°C, washed once with PBS 
and measured by flow cytometry (excitation 488nm, emission, exitation 535nm, FACSCanto II, 
BD). To exclude dead cells from the ROS measurement cells were double stained with DCFDA 
and PI. Accordingly, cells were stained for 30min with 5µg/ml PI in PBS at 4°C after the 
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DCFDA staining. The ROS scavenger N-Acetyl-L-Cystein (NAC) used in this study was 
previously dissolved in PBS (pH 7.4) before application.  
2.2.11 Western Blot Analysis and Cytosol-Mitochondria Fractionation 
Protein levels were investigated by Western blot analysis. Floating cells were treated with 
archazolid and the listed inhibitors for the indicated timeframes and subsequently lysed with 
phosphor-lysis buffer. Protein concentration was quantified by the bicinchoninic acid (BCA) 
protein assay according to the manufactures instructions. Equal amounts of the proteins were 
separated by SDS-PAGE (100V, 20min then 200V, 42min)(Bio-Rad System, Munich, Germany) 
and transferred onto nitrocellulose membranes by tank blotting (90V for 90min, 4°C). For 
detection of specific proteins, the ECL detection system (Amersham Pharmacia Biotech) or the 
Odyssey Infrared Imaging system version 2.1 (LI-COR Biosiences) was used.  
For cytosol-mitochondria fractionation cells were harvested, incubated with the digitonin-lysis-
buffer (20min, on ice) and centrifuged (10min, 1,300rpm, 4°C). The supernatant was collected 
(cytosolic fraction) and the pellet permeabilized with 0.1% TritonX-100 (15min, on ice) 
(mitochondrial fraction). Both fractions were centrifuged one more time (14,000rpm, 10min, 
4°C) to sediment the cell debris. Mitochondrial and cytosolic fractions were then processed like 
normal Western blot lysates.  
2.2.12 Statistics 
All experiments were performed at least three times in triplicates. All statistic analysis were 
performed using GraphPad Prism 5.0 software. 
One-way ANOVA with Turkey post-test and for two column comparison the unpaired Students 
t-test was performed as significance analysis. Error bars indicate standard errors of the mean 
(SEM).  
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3 RESULTS 
3.1 Effects of Archazolid on Anoikis Resistant Cancer Cells 
Anoikis resistant cancer cells are known to have highly invasive phenotypes (81). To overcome 
detachment induced cell death these cells have to activate several survival mechanisms probably 
influencing their response to chemotherapeutical treatment and enhancing their metastatic 
potential. Survival signals by adhesion are one of the major signaling cascades preventing anoikis 
(49).  
Therefore, adherent and detached cancer cells were investigated and compared concerning their 
anoikis resistance and responses to archazolid treatment.  
First, archazolid-functionality in inhibiting the V-ATPase was investigated in three different cell 
lines by surveying if acidification of intracellular compartments was blocked after archazolid 
treatment.  
Second, the influence of archazolid on adhesion time and manifestation, carried out by 
impedance measurements and confocal staining of adhesion-structures, was observed. 
Third, the impact of archazolid on anchorage independent growth as well as cell death induction 
was analyzed.  
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3.1.1 Alkalization of Lysosomes by Archazolid Treatment
To confirm that archazolid in fact inhibits the V-ATPase activity in our model cells, 
endolysosomal pH was monitored by staining cells with LysoTracker® dye (Figure 9). The dye is 
highly selective for acidic organelles where the fluorophore accumulates staining acid organelles 
red.  
Archazolid is a specific V-ATPase inhibitor functional in the nano-molar range (36). 
The V-ATPase is mostly located in the membrane of acidic organelles like the lysosomes or 
endolysosomes responsible for their acidification.  
Adherent T24 (urinary), MDA-MB-231 (mammary) and 4T1 (mouse mammary) cancer cells were 
treated with different archazolid concentrations (5 and 10nM) for 2h (T24 cells) and 4h (MDA-
MB-231 and 4T1). Thereafter cells were stained with LysoTracker® dye to monitor lysosomal 
pH in living cells using confocal microscopy.  
Figure 9 confirms that acidification of cell organelles is blocked by 5 and 10nM archazolid after 
2-4h of treatment in all investigated cell lines.  
 
Figure 9: Alkalyzation of lysosomes by archazolid treatment 
T24, MDA-MB-231 and 4T1 cells were treated with different archazolid concentrations (5 and 10nM) for 
2h (T24 cells) and 4h (MDA-MB-231 and 4T1). Thereafter cells were stained for 30min at 37°C with 
LysoTracker® dye to monitor lysosomal pH using confocal microscopy.  
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3.1.2 Adhesion Ability is Impaired after Archazolid Treatment
To prove that archazolid treatment has an impact on adhesion and therefore on the adhesion 
signaling cascade, an adhesion assay was performed (Figure 10).  
Adhesion molecules play a central role in anoikis induction and resistance. Anoikis resistant cells 
e.g. can change their integrin repertoire on the cell surface to circumvent integrin mediated death 
(IMD) or constitutively activate pro-survival downstream signals (56).  
Adherent T24 cells pretreated with archazolid (10nM, 24h) were harvested and subsequently 
seeded out for impedance measurements in the XCELLigence system. For this, cells were 
suspended in 200µl medium in E-plate-wells and adhesion time between treated an untreated 
cells was monitored as an increase in impedance, indicated as Cell Index occurring while cells 
adhere to the surface.  
The slopes of three independent experiments were calculated and the relative cell adhesion (%) 
was analyzed (Figure 10B). Figure 10 shows that adhesion time is prolonged after archazolid 
treatment, which suggests an effect of archazolid on cell adhesion.  
If adhesion is altered by archazolid treatment one could assume that there is also an impact on 
the pro-survival signaling cascade. 
Figure 10: Prolonged adhesion time after archazolid treatment. 
Adherent T24 cells were pretreated with archazolid (10nM, 24h) or left untreated.  
The kinetics of cell adhesion was subsequently measured using impedance measurement in the 
XCELLigence system over 4h.  
A: One representative graph out of three independent experiments is shown. 
B: The slopes (Cell Index/Time) of three independent experiments conducted in triplicates were 
calculated and the relative cell adhesion (%) was analyzed were control cells are represented as 100% 
adhesion. Archazolid treated cells show a reduced adhesion compared to control cells. 
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3.1.3 Changes in Focal Adhesion 
Adherent, archazolid treated cells were further analyzed by confocal microscopy to investigate 
changes in the focal adhesions. Therefore, cells were pretreated with archazolid (10nM, 24h) and 
subsequently seeded on fibronectin coated slides for 30min at 37°C. During the adhesion process 
cells develop focal adhesions, which can be stained by an antibody recognizing vinculin, a central 
protein in the focal adhesion plaques, and F-actin by rhodamine-phalloidin. Both proteins co-
localize in focal adhesion shown by the merged picture (Figure 11). 
Archazolid treatment clearly influences focal adhesion formation. Compared to control cells 
there is less vinculin clustering on the cell periphery. After treatment a more regular distribution 
of mature focal adhesions was observed.  
 
Figure 11: Changes in focal adhesions by archazolid treatment 
T24 cells were prestimulated with archazolid (10nM, 24h) or left untreated, then harvested, suspended 
and seeded on fibronectin coated slides for 30min, at 37°C. After 30 min cells will form first focal 
adhesions with the surface. Cells were then fixed, permeabilized and stained for confocal microscopy. 
Control cells show more vinculin clustering on the cell periphery then archazolid treated cells.  
The experiment was conducted three times in triplicates.  
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3.1.4 Archazolid Impairs Anchorage Independent Growth and Induces 
Anoikis in Invasive Cancer Cells 
To show anoikis resistance of the invasive cancer cell lines T24, 5637 (urinary), MDA-MB-231 
and 4T1 cells were grown in an anchorage-independent environment (Figure 12 and Figure 13) 
and subsequently analyzed for cell viability and cell death.  
3.1.4.1 Colony Formation Assay 
T24 cells were embedded in a soft agar layer without contact to ECM components or other cells 
to mimic anchorage independent growth. Untreated cells formed viable colonies after nine days 
of cultivation (Figure 12A, left, below) indicating anoikis resistance.  
Pretreatment of adherent T24 cells with archazolid (1nM, 10nM, 24h) impaired anchorage-
independent growth as shown by a reduction of viable colonies in the soft agar colony formation 
assay (Figure 12A left). Inhibition of colony formation in T24 cells could also be observed by the 
V-ATPase inhibitor concanamycin (Figure 12A right) suggesting a V-ATPase dependent effect. 
To exclude apoptosis to be responsible for the obtained results, adherent, 24h treated cells were 
analyzed for cell death induction. Permeabilized cells were stained with PI to measure the sub-G1 
DNA content as DNA fragmentation occurs during the apoptotic process (Figure 12B).  
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Figure 12: Anchorage independent growth is reduced by archazolid pre-treatment. 
A: T24 cells were pretreated with archazolid (1 and 10nM, 24h), concanamycin (1, 5, and 10nM, 24h) or 
left untreated (Co) and subsequently cultured in a soft agar layer for nine days. Anchorage independent 
growth was analyzed by counting stained colonies (MTT). Bars represent the percentage of colony 
formation compared to control cells. ***P< 0.001, n=3. Lower left: Representative colonies of archazolid 
treated and untreated T24 cells are shown.  
B: Adherent T24 cells were treated with archazolid for 24h (10nM). Apoptotic cell death was investigated 
as described in materials and methods. Bars represent the percentage of apoptotic cells as mean ± SEM 
of three independent experiments conducted in triplicates. 
RESULTS  32 
3.1.4.2 Analyzing Cell Death Induction in Detached Cells   
To further analyze effects of archazolid on anoikis, cells were kept in a detached status using 
poly-HEMA coated culture dishes and medium supplemented with methylcellulose to prevent 
massive cell aggregation. This setup was used for all further experiments with floating cells.  
Treatment with archazolid (10nM) induced anoikis in detached cancer cell lines T24, 5637 and 
4T1 after 48h and MDA-MB-231 after 72h, respectively (Figure 13). 
 
 
 
 
Figure 13: Induction of anoikis in detached cells by archazolid
Detached T24, 5637 and 4T1 cells were treated with different concentrations of archazolid for 48h and 
analyzed for apoptotic cell death. ***P<0.001, n=3. Detached MDA-MB-231 cells were treated with 
archazolid (10nM) for 72h and apoptotic cells were quantified by flow cytometry as described in materials 
and methods. *P<0.05, n=3. Bars represent the relative induction of apoptosis compared to control cells. 
Bars always represent the mean ± SEM of three independent experiments done in triplicates.  
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3.1.5 Cell Death Induction in Adherent and Floating Cells by Archazolid
To investigate the impact of detachment on cell death induction by archazolid adherent and 
floating cells were treated with archazolid (10nM, 24h or 48h) or left untreated.  
As detachment and thereby loss of survival signals also affects anoikis resistant cells, the basal cell 
death level was expected to be elevated in floating cells (Figure 14). Noteworthy, archazolid did 
neither induce apoptosis in adherent nor floating cells after 24h of treatment compared to the 
respective control cells.  
 
 
Cell death by archazolid did not occur before 48h of treatment.  
To compare the cell death induction of adherent and floating cells independently of the basal cell 
death level, specific apoptosis was calculated as ?????????????????
???????????
∗ 100.  
Calculating specific apoptosis, adherent T24 cells show a higher sensitivity towards archazolid 
after 48h then floating cells (Figure 15) pointing to death resistance or chemoresistance 
mechanisms induced by detachment.  
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Figure 15: Adherent T24 cells are 
more sensitive to archazolid then 
floating cells 
Adherent and floating T24 cells were 
treated with archazolid for 48h (1, 2, 10 
and 20nM). Apoptotic cell death was 
investigated as described in materials and 
methods. Bars represent the specific 
apoptotic rate compared to control as 
mean ± SEM of three independent 
experiments done in triplicates. 
***P<0.05. 
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Figure 14: Influence of detachment 
on basal cell death level 
Adherent and floating T24 cells were 
treated with archazolid for 24h (10nM). 
Apoptotic cell death was investigated as 
described in materials and methods. Bars 
represent the percentage of apoptotic 
cells as mean ± SEM of three 
independent experiments conducted in 
triplicates.  
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3.2 Archazolid treated tumor cells lose their metastatic potential in vivo 
The anoikis inducing effect of archazolid was hypothesized to affect the invasive potential of 
tumor cells in vivo. To confirm this hypothesis an in vivo model based on the 4T1-Luc2 mouse 
mammary tumor cell line has been used. These cells are highly metastatic and disseminate quickly 
to the lungs when injected intravenously and are therefore resistant to anoikis as anoikis 
resistance is a precondition for metastasis. 4T1-Luc2 cells are further engineered to express a 
luciferase reporter to enable real time monitoring of developing tumors by live imaging. 
As shown in Figure 16 4T1-Luc2-injected animals formed easily detectable lung metastases, 
however 4T1-Luc2 cells pretreated with archazolid (10nM, 24h) showed a significant reduction of 
lung metastases (Figure 16B, left). Archazolid treated cells did not show signs of apoptosis at the 
time of the intravenous injection (Figure 16B, right).  
In vivo experiments were performed by Laura Schreiner and Rebekka Kubisch. 
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Figure 16: Pretreatment of invasive breast cancer cells with archazolid reduced metastasis in 
mice lungs 
4T1-Luc2 cells were pretreated with archazolid (10nM, 24h) or left untreated and subsequently injected 
(1x105) in the tail vain of 10 BALB/cByJRj mice per group.  
A: At day eight after inoculation lung metastases were monitored by bioluminescence read out by 
dorsoventral and ventrodorsal mice imaging.  
B: Bioluminescence signals were calculated as total flux/area. Pretreated adherent cells were tested for 
apoptotic cell death three times in triplicates. Bars represent the mean ± SEM. *P<0.05, n=10 
Performed by Laura Schreiner and Rebekka Kubisch. 
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3.3 Underlying Mechanisms of Anoikis Induction by Archazolid  
3.3.1 Archazolid Treatment Reduces Active ß1 Integrin on the Cell Surface 
of Detached Cells 
Integrin β1 is a major player responsible for cell adhesion to the ECM. Activated by attachment 
integrin β1 signaling inhibits anoikis and promotes cell survival (82). 
In Figure 10 it has been shown that treatment with archazolid impairs adhesion abilities of T24 
cells after 24h of treatment, suggesting an effect of archazolid on adhesion molecules such as 
integrins.  
Figure 17A shows that the level of active integrin β1 (analyzed by an integrin β1 conformation 
specific antibody) is similar between adherent and detached (24h) T24 cells. However, archazolid 
treated (10nM, 24h), detached cells display a reduction of active integrin β1 compared to 
detached control cells, whereas surface level of total integrin β1 was not affected by archazolid 
treatment (Figure 17B).
 
Figure 17: Archazolid treatment decreases active integrin β1 on the cell surface 
A: Cell surface level of integrin β1 was analyzed by an antibody recognizing only active integrin β1 and 
compared between adherent and detached (24h) T24 cells. No differences in surface level of active 
integrin β1 between adherent and floating cells could be detected. 
B: Levels of total and active integrin β1 on the cell surface of archazolid treated (24h), floating T24 cells 
was investigated by antibody staining and flow cytometry. Active integrin β1 is reduced on the cell surface 
of archazolid treated cells ***P<0.001, n=3 
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3.3.2 FAK Activity is Decreased in Detached Archazolid Treated Cells
The focal adhesion kinase is recruited and activated by integrins binding to their ECM ligands, 
leading to the activation of several downstream survival signals via the PI3K/Akt and the 
Raf/MEK/ERK pathway (47). As the FAK is a major downstream kinase of integrins we were 
interested if activating phosphorylations of the FAK changed due to archazolid treatment. As 
shown in Figure 18A archazolid treated, floating T24 cells showed reduced phosphorylation of 
FAK in the total cell lysate after 24h and 48h of treatment. Noteworthy, control cells detached 
for 24h and 48h show a strong phosphorylation of FAK. 
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Figure 18: Archazolid treatment impairs FAK phosphorylation 
A: The phosphorylation state of FAK after archazolid treatment (24h and 48h, T24 cells) is shown by 
Western blot (B) with the corresponding quantification of three independent experiments.  
*P<0.05, n=3 
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3.3.3 Archazolid Induces Activation of Caspase-8 and Downregulation of 
c-FLIP 
To further reveal the mechanisms of anoikis induction by archazolid, activity of caspase-8 was 
determined. As caspase-8 induction is a known hallmark of anoikis and the extrinsic apoptotic 
pathway, caspase activity was measured in cell lysates using a fluorophore generating substrate for 
caspase-8. Floating T24 and 4T1 cells were stimulated for 48h with different archazolid 
concentrations, displaying a significant increase in caspase-8 activity compared to control cells 
(Figure 19A). TRAIL was used as a positive control.  
Moreover c-FLIP, a well-described inhibitor of caspase-8 (83) which contributes to anoikis 
resistance by overexpression in malignant cells (55) is reduced after 48h of treatment in floating 
T24 cells (Figure 19B).  
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Figure 19: Activation of caspase-8 and reduction of caspase-8 inhibitor c-FLIP 
A: Treated (48h) T24 and 4T1 cells were harvested and the total cell lysate was analysed for caspase-8 
activity. TRAIL as a positive control was applied 1h before activity measurement. Upper panel: 
Evaluation of three indipendent experiments for T24 and 4T1 cells presented as relative fluorescence unit  
per minute (ΔRFU/min). ***P<0.001, n=3. Lower panel: Representative graph of caspase-8 activity 
measurement over 5h (T24 cells) displayed as relative fluorescence unit (RFU).  
B: Left: The level of caspase inhibitor c-FLIP was investigated by Western blot in T24 cells after 
archazolid treatment (48h). Right: Quantification of three independent experiments. *P<0.01 
Bars always represent the mean ± SEM of three independent experiments conducted in triplicates.  
All Western blot experiments show a representative blot out of three independent experiments. 
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3.3.4 Archazolid Treatment Rapidly Induces BIM Translocation to 
Mitochondria Leading to Cytochrome C Release 
As the Bcl-2 Protein BIM is considered to be the major player of the intrinsic mediated anoikis 
pathway (70) we analyzed BIM expression after archazolid treatment. Figure 20A indicates that 
cellular BIM expression is not affected by archazolid treatment for 5h, however BIM is 
translocated and enriched at mitochondria at early time points after archazolid exposure (i.e. 3h 
and 5h, T24 and 4T1 cells). Interestingly, the translocation to mitochondria is observed to be a 
cell type specific effect as MDA-MB-231 cells show a BIM reduction and MCF7 cells an equal 
level for treatment and control.  
BIM localized at the mitochondrial outer membrane is responsible for Bax and Bak activation 
leading to the release of cytochrome C to the cytosol and subsequently to apoptosis (84). A 
decrease of cytochrome C in the mitochondrial fraction of T24 cells was observed after 24h and 
48h of treatment (Figure 20B). Obviously both the intrinsic as well as the extrinsic pathway 
(Figure 19) is activated by archazolid.  
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Figure 20: BIM translocation to 
mitochondria and cytochrome C 
release by archazolid 
A Western blot analysis of BIM 
expression in whole cell lysate of 
untreated and archazolid treated 
T24 cells after 5h. BIM level was 
analyzed in the mitochondrial 
fraction of cells treated with 
archazolid for a few hours (3 and 
5h, T24, 4T1, MDA-MB-231 and 
MCF7 cells). Immunoblotting for 
mitochondrial COX IV and VDAC 
was employed as control for 
protein loading. Quantification of 
multiple independent experiments 
was performed. *P<0.05 
 BIM translocates to the 
mitochondria in T24, and 4T1 
archazolid treated cells. 
B: The mitochondrial cytochrome 
C level after archazolid treatment 
(24h and 48h) is shown by Western 
blot analysis of mitochondrial 
protein of T24 cells. COX IV 
immunoblotting served as loading 
control. 
Cytochrome C decreases in the 
mitochondrial fraction of T24, 
treated cells.  
All blots show a representative blot 
out of three independent 
experiments. 
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3.4 Archazolid Triggers Mechanisms Opposing Anoikis 
Chemoresistance is a major challenge in tumor therapy.  
Anoikis challenges tumor cells to develop elaborated survival strategies leading to anoikis 
resistance. Nevertheless, additional chemoresistance strategies can generate highly metastatic 
cancer phenotypes. Elucidating these strategies can help to develop functional combination 
therapies.  
  
Archazolid treatment triggered survival mechanisms in anoikis resistant cancer cells like a strong 
degradation of the pro-apoptotic protein BIM and a beneficial increase in reactive oxygen 
species, which can function as pro-survival second messengers.  
Therefore, BIM degradation was more deeply investigated and a combinatory approach by using 
drugs inhibiting BIM degradation as well as ROS induction together with archazolid was tested. 
3.4.1 BIM Degradation after Prolonged Treatment 
Sustained exposure of detached cells to archazolid results in a strong reduction of the 
proapoptotic molecule BIM (Figure 21A), which is due to proteasomal degradation shown by the 
use of two proteasome inhibitors (MG-132 and bortezomib) (Figure 21B).  
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Figure 21: BIM degradation after prolonged archazolid treatment and rescue with proteasome 
inhibitors 
A BIM degradation: BIM protein level in whole cell lysate and mitochondrial fraction after prolonged 
treatment with archazolid (24h, 48h) was analyzed by Western blot. Actin, COX IV and β-Tubulin were 
used as loading control.  
B BIM rescue: A combination of archazolid (10nM) with proteasome inhibitor MG-132 (24h) (left) or 
bortezomib (BOR, 48h) (right) was used to investigate changes in BIM protein level by Western blot in 
T24 cells. The combination was applied simultaneously to the cells at time of detachment. Three 
independent experiments were quantified using Image J software. *P<0.05 
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3.4.2 Targeting BIM Degradation by Proteasome Inhibitors to Increase Cell 
Death Induction 
Combination of archazolid with the proteasome inhibitors MG-132 (100nM) and bortezomib 
(5ng/ml) induced significantly higher apoptosis rates synergistically induced in T24 cells 
(Figure 22) and rescued BIM from degradation as shown in Figure 21B. 
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Figure 22: Inhibition of the proteasome triggers archazolid induced anoikis 
Floating T24 cells were either treated with archazolid (10nM, 48h) alone or in combination with the 
proteasome inhibitor MG-132 or bortezomib (BOR) for. Subsequently, apoptosis induction was 
determined as described in materials and methods. ***P<0.001 
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3.4.3 Moderate ROS Induction after Archazolid Treatment as Pro-Survival 
Strategy to Circumvent Anoikis  
Reactive oxygen species are discussed to play a major role in anoikis protection, as they can 
function as second messenger activating pro-survival kinases (50,51,85).  
Intracellular ROS were analyzed by flow cytometry. A fluorescent dye converted by ROS was 
added to the cells for 30min, 37°C.  
Interestingly, archazolid treatment increased ROS level significantly after 16 to 48h (Figure 23 
and Figure 24) compared to floating control cells. Archazolid treated cells reach ROS levels of 
adherent control cells indicating a non-toxic level of ROS, as ROS can also function as second 
messenger activating pro-survival signals also involved in BIM regulation and degradation. This is 
considered one of the anoikis escape strategies used by invasive tumor cells (50,52).  
Figure 23: Beneficial ROS generation by archazolid treatment 
Upper panel: Archazolid induces generation of ROS in T24 cells after 24h and in 4T1 cells after 16h of 
treatment. ROS generation was measured as indicated in materials and methods. Bars represent the mean 
± SEM of three independent experiments conducted in triplicates. ***P<0.001, *P<0.05.  
Lower panel: One representative graph of a simultaneous PI (cell death) and ROS measurement in T24 
cells displayed as dotplot and the corresponding histogram.  
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Inhibition of ROS generation by the antioxidant N-Acetyl-L-Cystein (NAC) (Figure 24A, left) 
rescues BIM from proteasomal degradation induced by archazolid alone (Figure 24B) confirming 
the involvement of ROS in BIM degradation. NAC as well was able to increase cell death in 
combination with archazolid (Figure 24A right) suggesting a role for ROS in anoikis induction 
and inhibition.  
 
 
 
 
 
 
 
Figure 24: BIM rescue by ROS inhibition 
A: Left: Archazolid induces generation of ROS, which can be inhibited by the antioxidant NAC after 48h 
of treatment. ROS generation was measured as indicated in materials and methods. ***P<0.001 
Right: Detached T24 cells were treated with archazolid (5nM) alone or in combination with NAC 
(10mM) for 48h. Induction of apoptosis was measured by PI staining and flow cytometry. **P<0.01  
Bars represent the mean ± SEM of three independent experiments conducted in triplicates.. B: ROS 
generation is involved in BIM degradation by archazolid. Western blot analysis showed that ROS 
scavenger in combination with archazolid (24h) rescued the degradation of BIM. 
One representative blot out of three independent experiments is shown.  
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3.4.4 Kinase-Involvement in Anoikis Resistance
Additionally, kinases involved in anoikis resistance (Akt, ERK, c-Src) were affected by 
detachment of T24 cells showing an early increases of their phosphorylation, whereas 
phosphorylation of c-Src kinase was unchanged. Akt and ERK are therefore mainly responsible 
for activating anoikis resistance after detachment. At a later time point the phosphorylation of 
Akt and ERK decreased again indicating a restored balance of pro-survival and pro-apoptotic 
signaling (Figure 25).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Phosphorylation of Akt and ERK is increased early after detachment but decreased 
again after 24h 
Left: T24 cells were kept in suspension for 6h and 24h and compared to adherent cells. Phosphorylation 
of Akt was analyzed by Western blot. Actin served as loading control. One representative blot out of 
three independent experiments is shown.  
Right: T24 cells were kept in suspension for 3, 5h and 24h in comparison to adherent cells. 
Phosphorylation of ERK and c-Src was analyzed by Western blot. Actin served as loading control. One 
representative blot out of three independent experiments is shown.  
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To further investigate the impact archazolid has on Akt, ERK and c-Src phosphorylation, 
floating, treated T24 cells were examined by Western blot analysis for the indicated 
phosphorylations.   
Treatment of floating cells with archazolid (10nM, 48h) even further increased the 
phosphorylation of Akt compared to untreated control cells. The phosphorylation of ERK (48h) 
and c-Src (48h) did not change due to archazolid treatment (Figure 26), together suggesting 
archazolid induced counter mechanisms. 
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Figure 26: Influence of archazolid treatment on Akt, ERK and c-Src phosphorylation 
Activation of Akt, ERK and c-Src kinases by archazolid treatment was investigated after 48h for Akt and 
ERK and after 24h for c-Src using Western blot analysis of their phosphorylated sites. All Western blot 
experiments show a representative blot out of three independent experiments. For Akt kinase activation 
two independent experiments were quantifies using Imaje J software. 
All experiments were performed with T24 cells. 
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To more deeply elucidate the role of Akt, ERK and c-Src kinases, inhibitors of these proteins 
were used and the effect on apoptosis induction and BIM level was analyzed.  
Employing specific inhibitors (LY 294002 (Akt), PD 98059 (ERK) and Saracatinib (c-Src)) led to 
apoptosis and prevented the decrease of BIM in archazolid treated cells (Figure 27).  
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Figure 27: Inhibition of Akt, ERK and c-Src induces anoikis and rescues BIM 
Left panel: Floating T24 cells were treated with Akt-, ERK-, and c-Src-inhibitors for 48h and apoptotic 
cell death was analyzed. Bars represent the percantage of apoptotic cells of the whole population in mean 
± SEM of three independent experiments conducted in triplicates. ***P<0.001, **P<0.01, *P<0.05. 
Right panel: Application of inhibitors i.e. LY 294002 (Akt), PD 98059 (ERK) or Saracatinib (c-Src) 
together with archazolid were used to analyse changes in BIM protein level. Changes of Akt and ERK 
were investigated after 48h and of c-Src after 24h. 
All Western blot experiments show a representative blot out of three independent experiments. All 
experiments were performed with T24 cells 
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4 DISCUSSION 
This work disclosed that pharmacological inhibition of V-ATPase by archazolid induces anoikis 
in invasive cancer cells, which contributes to the distinct anti-metastatic action of archazolid in 
vivo. Thus we could add important new information regarding the role of V-ATPase in cancer 
dissemination. 
4.1 The V-ATPase in Cancer Cells 
Up to now it has been reported that the abundance of V-ATPase on the plasma membrane of 
tumor cells correlates with their invasiveness. Several well-known V-ATPase inhibitors like 
concanamycin and bafilomycin were shown to lead to growth arrest and cell death induction in a 
variety of tumor cells (2,86,87). Also the newly developed V-ATPase inhibitors salicylihalamide 
(88) and NIK-12192 (89) have demonstrated anti-tumor activity although the exact molecular 
mechanisms of V-ATPase inhibitors leading to inhibition of tumor cell invasion remain to be 
elucidated. Cell surface located V-ATPase is hypothesized to create a proton efflux leading to an 
acidic pericellular microenvironment that promotes the activity of pro-invasive proteases and/or 
rescues tumor cells from intracellular acidification due to increased glycolysis, which can 
otherwise lead to apoptosis (8,90). However, evidence accumulates that the endolysosomal V-
ATPase is important as antitumoral/antimetastatic target. Recent work in our group showed that 
V-ATPase inhibition by archazolid impairs endocytotic traffic of migratory signaling molecules 
such as Rac1 and EGF-R, which is pivotal for directed and polarized cell movements (40). 
Abrogation of endosomal trafficking by V-ATPase inhibition was reported to also have impact 
on tumor growth and apoptosis induction suppressing activation of important signaling 
molecules such as Rab27B or activation of caspase-8 (91,92).  
We showed that V-ATPase inhibition influences anoikis resistance in invasive cancer cells by 
triggering anoikis pathways and impairing survival-receptor signaling. This, presumably by 
inhibition of the endolysosomal V-ATPase, as receptor recycling and autophagy play important 
roles in anoikis induction and resistance. 
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4.2 Relevance of Anoikis in Normal and Malignant Cells 
This work using archazolid as a tool to inhibit V-ATPase provides important information on 
regulation of anoikis and especially anoikis resistance in cancer.  
From a physiological point of view, anoikis is an important mechanism to remove cells, which are 
currently not in their correct location, lacking a correct adhesion and thus guaranteeing tissue 
homeostasis and preventing dysplastic growth. In other words most cell types need proper cell-
cell and cell-matrix interactions to survive. Cell to ECM interactions occur mainly via specific 
integrins and trigger a cascade of pro-survival and proliferative signals (47,52). 
Metastatic cancer cells in contrast to non-malignant tissue cells, do not require adhesion to the 
ECM to survive and proliferate, they are mostly insensitive to anoikis and in fact resistance to 
anoikis is a key regulator for tumor cell invasion and metastasis (52) (Figure 28). Tumor cells use 
various strategies to acquire anoikis resistance such as the constitutive activation of survival 
pathways (PI3K/Akt, MEK/ERK and c-Src family kinases), alteration of the integrin expression 
pattern or generation of oxidative stress and inhibition of apoptotic pathways (50,52,55,93).  
DETACHMENT
ANOIKIS
CELL DEATH
MALIGNANT
CELL
METASTASIS
SURVIVAL IN
THE CIRCULATION
ECM
Figure 28: Anoikis resistance as prerequisite for tumor cell metastasis  
Normal tissue cells are programmed to anoikis when detached from their respective ECM. Malignant 
cells can acquire anoikis resistance by several strategies to survive in the circulation. This is a precondition 
to form metastases in distant tissues or organs. 
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4.3 Anoikis Induction by Archazolid a V-ATPase Inhibitor 
How a V-ATPase inhibitor could possibly affect anoikis induction in invasive cancer cells is a 
challenging issue to solve. It is known that detachment can induce autophagy as a survival 
mechanism preventing anoikis. Inhibition of autophagy increased caspase-3 activity in detached 
cells (72) and BIM was thought to influence autophagy by interacting with beclin-1 and inhibiting 
autophagosome formation (73). It has been shown that integrin β1 inhibition directly correlates 
with autophagy induction suggesting an important role in anoikis (74). V-ATPase inhibition on 
the other hand is known to block late stages of autophagy due to alkalization of lysosomes and 
thereby inhibiting protein degradation in autolysosomes. Archazolid is a very potent V-ATPase 
inhibitor alkalizing cell-compartments within hours as shown in Figure 9. Treatment of different 
adherent cancer cell lines led to reduced lysosome acidification already after 2-4h indicating an 
early stop of protein degradation, depriving anoikis resistant cells of this escape mechanism. 
 V-ATPase inhibition might also affect integrin signaling as integrin activities are dependent on 
fast endocytosis rates and V-ATPase regulates receptor recycling via acidification of endosomes 
and lysosomes (3,94,95). It is known, that block of endosome acidification leads to trafficking 
inhibition probably because of a general block in the formation of carriers important for the 
formation of clathrin-coated-vesicles (CCV) (94). CCV formation is the major endocytotic 
pathway in mammalian cells (96). Also an accumulation of receptors on the cell surface due to 
blocked internalization is a reported effect of V-ATPase inhibition (40,94,97).  
That is why it has been hypothesized that V-ATPase inhibition affects anoikis induction as 
receptor recycling is attenuated consequently influencing membrane receptor signaling. 
In fact, we could show that archazolid induces anoikis in invasive urinary and breast cancer cells. 
Anoikis is provoked by a reduction of active integrin ß1 on the cell surface, an activation of 
caspase-8 and an early translocation of BIM to the mitochondria followed by release of 
cytochrome C. Of note, archazolid treated breast tumor cells injected (i.v.) in mice showed a 
reduced formation of lung metastasis (Figure 16). This study further identified counter 
mechanisms induced by archazolid treatment like a strong proteasomal downregulation of BIM 
provoked by generation of ROS and active pro-survival kinases. 
4.3.1 Impaired Adhesion after Archazolid Treatment  
As integrins function as the main cellular receptors for ECM-cell interactions they are assembled 
in specific adhesive structures like focal adhesions, which directly link the cytoskeleton to the 
ECM. In mature focal adhesions integrins are in an active conformation and constantly ligand-
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bound (98). Integrin-ECM interactions stimulate focal adhesion formation functioning as a 
signaling hub by accumulating multiple kinases and scaffold proteins (99). Hence, impaired 
adhesion as seen by archazolid (Figure 10) pretreatment implies a reduced functionality of focal 
adhesions. This assumption was strengthened as staining of vinculin by a fluorescent antibody 
and visualization by confocal microscopy revealed that archazolid treatment altered vinculin 
incidence and localization (Figure 11). Vinculin is a major structural protein in the focal 
adhesions and often used as focal adhesion marker (100,101). The images showed that after 
treatment vinculin clustering at the periphery of the cells was reduced. Archazolid treated cells 
develop more spike-like focal adhesions, likely to compensate for a reduced functionality proved 
by the adhesion assay. As reduced adhesion ability might trigger enhanced focal adhesion 
formation to level up the output.  
4.3.2 Archazolid Induces Cell Death in Anoikis Resistant Cancer Cells by 
Distinct Activation of Apoptotic Pathways 
In experimental anoikis models, cells are forced to grow anchorage independent, which triggers 
the above-mentioned stress and survival responses leading to a selection of the “fittest” seen by 
an elevated apoptosis level of floating cells compared to adherent ones (Figure 14). There are 
reports that an oncogenic epithelial-mesenchymal transition (EMT) also is characterized by 
anoikis resistance. EMT is a process normally occurring during development forming the primary 
mesenchyme. Epithelial cells undergoing EMT loose the necessity of attachment for their 
survival, acquire more motility, change their morphology and their repertoire of adhesion 
molecules such as E-catherin and additionally silence epithelium-specific genes and activate 
mesenchymal-specific genes. It has been shown that a subgroup of breast cancer cell lines with 
especially invasive properties had mostly mesenchymal gene-expression signatures compared to 
more luminal like cell lines (102–104). Evidently, there is a close relationship between oncogenic 
EMT and acquisition of anoikis resistance. We could demonstrate, that on the one hand cell 
death slightly increases by detachment and on the other hand anoikis resistance is activated by 
Akt and ERK induction (Figure 25). Taking this into account it would be very interesting to 
further investigate if an EMT like process occurs in our cell lines during extended detachment. 
Anoikis resistance is often accompanied by resistance to chemotherapeutics, supported by our 
observation that adherent cancer cells are significantly more sensitive to archazolid then detached 
cells (Figure 15). ECM/integrin signaling can protect cancer cells from drug induced apoptosis by 
activation of the Akt and ERK signaling pathway (63). 
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 The clear effect of archazolid on anchorage independent growth of cancer cells as well as the 
induction of cell death in cells forced to stay detached is thus remarkable (Figure 12 and 
Figure 13). Even more so having learned that archazolid treatment itself potently induces anoikis 
resistance via ROS generation and activation of Akt, which together with constitutive active ERK 
and c-Src leads to the removal of BIM, which will be further discussed in the next sections 
(Figure 23, Figure 26 and Figure 27).  
Obviously, it is important to find out how a compound like archazolid finally achieves anoikis 
induction, meaning, which pathways are involved.  
Anoikis is characterized as an apoptotic cell death executed by features of the intrinsic and 
extrinsic apoptotic pathway and the loss of survival signals by unligated anchorage proteins like 
integrins (75). The extrinsic pathway is initiated by caspase-8 activating effector caspases or 
promoting mitochondrial cytochrome C release (75,105).  
Archazolid evidently uses the extrinsic apoptotic pathway as shown by a downregulation of 
c-FLIP and a distinct caspase-8 activation (Figure 19). Recruitment of caspase-8 and its activation 
has been shown to occur by loss of anchorage to ECM and unligated integrins (53,106). Integrins 
with the β1 subunit in common are the major receptors for ECM components responsible for 
cell-ECM interactions (47). Interestingly, cell surface β1 integrin of cancer cells, floating for 24h 
was still as active as in adherent cells, suggesting an inside-out integrin activation supporting 
anoikis resistance of these cells (107). Importantly, archazolid reduced the amount of active 
integrin β1 on the cell surface leaving the total integrin level constant probably through an altered 
receptor recycling (Figure 17).  
4.3.3 Impacts on the Integrin Downstream Signaling by Archazolid 
Treatment 
In consequence, downstream pro-survival signals like the phosphorylation of one key player in 
anoikis protection, FAK (82) was affected by archazolid treatment (Figure 18). FAK together 
with c-Src then interact with numerous molecules recruiting and activating other pro-survival 
proteins like PI3K/Akt or ERK (46). We observed that T24 cells, shortly after detachment (5h) 
induce anoikis resistance by activating Akt and ERK which decreases when cells were detached 
for 24h suggesting a restored balance between apoptotic and survival players. For c-Src kinase the 
phosphorylation was not changed due to detachment over 3, 5 and 24h compared to adherent 
control cells implying no direct involvement in the immediate anoikis resistance (Figure 25).  
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Unexpectedly, we did not observe inhibitory effects of archazolid on either Akt, ERK or c-Src 
but an activation of Akt which is considered to be part of the counter, pro-survival mechanism 
induced by archazolid (Figure 26). 
4.3.4 BIM: First Activated then Inhibited by Archazolid Treatment  
Anoikis due to the intrinsic pathway is mainly initiated by BIM (108). BIM, a member of the Bcl-
2 family activates Bax and Bak which leads to the permeabilisation of the outer mitochondrial 
membrane and the release of cytochrome C to the cytosol thereby activating a caspase cascade 
inducing cell death (60,84). In fact, BIM has been reviewed as a potential target for tumor therapy 
as BIM promotes anoikis in many tumor cell types and BIM suppression supports metastasis and 
chemoresistance (70). BIM regulation is dependent on cell surface molecules like integrins and 
the epidermal growth factor receptor (EGFR) (54).  
We found that BIM was rapidly translocated to the mitochondria by archazolid treatment 
followed by cytochrome C release (Figure 20) pointing to an involvement of the intrinsic 
apoptotic pathway.  
4.4 Resistance Mechanisms after Archazolid Treatment 
Of note BIM inhibition seems to be also the major factor used by T24 and MCF 7 cells to induce 
resistance to anoikis as BIM gets strongly degraded at a later time of archazolid exposure 
(Figure 21A). In MDA-MB-231 cells, a highly invasive breast cancer cell line, this degradation 
could even be observed shortly after archazolid treatment in detached cells (Figure 20) indicating 
that the ability to control BIM is connected to the metastatic potential. The fact that rescue of 
BIM degradation (Figure 21B) employing proteasome inhibitors MG-132 and bortezomib 
synergistically increased archazolid induced cell death underscores the important role of this BH-
3 only protein in the regulation of anoikis and its failure (Figure 22).  
As kinases such as ERK, Akt and c-Src are known to regulate BIM degradation and expression it 
was tempting to employ specific kinase inhibitors in order to gain further insight in the archazolid 
triggered BIM removal and thus chemoresistance (109). Akt and ERK can both phosphorylate 
BIM to be proteasomal degraded or sequestered, thereby having an immediate effect on BIM 
clearance in the cytosol (58,109). The relevance of these kinases in survival was shown by the fact 
that kinase inhibitors alone at high concentration induce anoikis. Co-stimulation of archazolid 
with moderate concentrations of kinase inhibitors rescued BIM, indicating that cells actively 
block BIM activation by various pathways in response to archazolid treatment (Figure 27). This 
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further underlines the highly efficient survival and anoikis resistance mechanisms of invasive 
tumor cells and highlights compounds such as archazolid still inducing cell death.  
Additionally, ROS are considered critical players in anoikis resistance. Integrin mediated adhesion 
induces a transient burst of high ROS levels transducing survival signals by activation of c-Src 
kinases. Activated c-Src kinases trans-phosphorylate EGF-receptor ligands, activating ERK and 
PI3K/Akt pathways. Scavenging of ROS in adherent cells leads to BIM induction and cell death 
(50,51). ROS are also recognized as second messenger in cell growth, proliferation, adhesion and 
cell spreading in untransformed cells (110). Induction of ROS in tumor cells is correlated to 
tumor initiation and progression as well as with tumor invasiveness (111). Anoikis sensitive cells 
show decreased ROS levels after detachment correlating with cell death induction (50). Now, we 
discovered that archazolid treatment of floating cells resulted in elevated ROS levels compared to 
untreated cells, but did not exceed the steady state level of ROS in untreated adherent cells 
(Figure 23). Still, cell death was induced by archazolid. This elevated ROS could be a further 
explanation for the prominent removal of BIM protein. We showed, in accordance to Giannoni 
et al. (50) that co-treatment of archazolid with a ROS scavenger led to increased cell death and 
increased BIM levels (Figure 24). Therefore, ROS must play a critical role in resistance to 
archazolid-induced anoikis.  
4.5 Conclusion and Outlook 
This study demonstrates that archazolid induces anoikis in highly invasive tumor cells by 
activation of the extrinsic and intrinsic apoptotic pathway. Anoikis induction is accompanied by 
initiation of highly productive resistance mechanisms especially removal of BIM by activation of 
Akt and induction of ROS. Understanding the mode of actions leading to cell death by 
archazolid treatment and the challenges of counter reactions can help gaining deeper insight in 
anoikis resistance mechanisms, chemoresistance and the metastatic transition of detached tumor 
cells.  
A clear characterization of anoikis resistance mechanisms depending on tumor cell type, drug 
treatment, EMT occurence and metastatic potential is therefore desirable to adjust 
chemotherapies or apply suitable combination drug therapies as metastasis is still the number one 
cause for death by cancer.  
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6 APPENDIX 
6.1 List of Abbreviations 
AKT         Protein kinase B 
ANOVA        Analysis of variance between groups 
ARCH         Archazolid A 
ATP         Adenosin-5’-triphosphat 
BCA         Bicinchoninic acid 
BCL-2         B-cell lymphoma 
BIM         Bcl-2 interacting mediator of cell death 
BSA         Bovine Serum Albumine 
CO         Control 
DISC         Death inducing signaling complex 
DMEM:F12       Dulbeccos’s Modified Eagle’s Medium 
DMSO         Dimethyl Sulfoxide 
ECM         Extracellular matrix 
EDTA         Ethylenediaminetetraacetic acid 
EGTA         Ethyleneglycoltetraacetic acid 
ERK         Extracellular signal-regulated kinase 
EtOH         Ethanol 
FACS         Fluorescence activated cell sorter 
FADD         Fas-associated death domain protein 
FAK         Focal adhesion kinase 
FCS         Fetal calf serum 
FLIP         FLICE-like inhibitory protein 
HFS         Hypotonic fluorochrome solution 
MAPK         Mitogen activated protein kinase 
MEK         Mitogen activated protein kinase kinase 
MTOR         mechanistic target of rapamycin 
MTT         Thiazolyl Blue Tetrazolium Bromide 
NAC         N-Acetyl-L-Cysteine 
RAF         Rapidly Accelerated Fibrosarcoma 
RAS         Rat sarcoma 
ROS         Reactive oxygen species 
SDS-PAGE       Sodium dodecyl sulfate – polyacrylamid-gelelectrophorese 
SRC         Sarcoma 
TRAIL         TNF related apoptosis inducing ligand  
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Lieber Michi, liebe Verena und liebe Sandra. Vielen Dank für die tollen drei Jahre. Wir haben alle 
zusammen angefangen und dadurch, finde ich, einen besonderen Zusammenhalt und ein gutes 
Gruppenklima gehabt. Aus der Doktorarbeit mit so vielen neuen guten Freundschaften zu gehen 
macht mich sehr glücklich. Danke. 
Auch allen anderen Mitgliedern des Arbeitskreises möchte ich hiermit aus ganzem Herzen 
danken. Ich gehe mit einem weinenden und einem lachenden Auge, da ich viele liebe Menschen 
vermissen werde.  
Ein riesiges Dankeschön geht an Benny. Dafür, dass du mich die drei Jahre aufgeheitert, 
unterstütz, bestärkt und ermutigt hast. Danke einfach dafür, dass du an meiner Seite warst.  
 
Meiner Familie und meinen Freunden möchte ich im Besondere noch danken.  
Meinen lieben Freunden, dass Sie immer an mir fest gehalten haben egal ob in Stuttgart oder 
München und einfach für ihre Freundschaft. Damit meine ich im Besonderen meine Julia, Miri 
und Mandy in Stuttgart und meine Lena und Micha in München.  
Lieber Martin, liebe Christa auch Euch möchte ich aus ganzem Herzen danken für Euer gutes 
Zureden und Zuhören und Unterstützen. Dafür, dass Ihr immer Zeit und Geduld für mich 
hattet.  
Meinem Papa, meiner Schwester Callo und meinem Bruder Paul danke ich für die 
immerwährende Unterstützung und Ermutigung, dass Ihr an mich und den Dr. Tini geglaubt 
habt und dafür, dass ich euch habe und ich auf euch bauen kann.  
 
 
 
     
 
 
